Metabolic Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
CYP2C enzymes are responsible for the oxidative metabolism of a diverse number of drugs for the treatment of type 2 diabetes mellitus, a severe metabolic disorder with high prevalence.
|
21939641 |
2011 |
Coronary Arteriosclerosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of CYP2C or CYP2J2 have a pathologic impact on coronary artery diseases.
|
21476972 |
2011 |
Drug abuse
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The described drug abuse cases suggest that an association between the presence of CYP2C and VKORC1 allelic variants and cocaine-induced interstitial lung damage is highly likely.
|
21766908 |
2011 |
Coronary Artery Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of CYP2C or CYP2J2 have a pathologic impact on coronary artery diseases.
|
21476972 |
2011 |
Peptic Ulcer
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We investigated whether eight functional SNPs in the CYP2C family of genes--CYP2C8*3 (rs11572080 and rs10509681), CYP2C8*4, CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C19*3, and CYP2C19*17--are associated with PUD in 1,239 Caucasian patients.
|
23267857 |
2013 |
Retinal Diseases
|
0.020 |
AlteredExpression
|
group |
BEFREE |
We found that CYP2C (localized in wild-type monocytes/macrophages) is upregulated in oxygen-induced retinopathy, whereas sEH is suppressed, resulting in an increased retinal epoxide:diol ratio.
|
24458713 |
2014 |
Hypertensive disease
|
0.040 |
Biomarker
|
group |
BEFREE |
Studies with rat genetic models of hypertension pointed to roles for the CYP2C and CYP4A arachidonic acid epoxygenases and ω-hydroxylases in tubular transport, hemodynamics, and blood pressure control.
|
25986599 |
2015 |
Retinal Diseases
|
0.020 |
PosttranslationalModification
|
group |
BEFREE |
Soluble epoxide hydrolase inhibition, which blocks breakdown and inactivation of CYP2C ω-3 LCPUFA-derived active metabolites, increased oxygen-induced retinopathy and CNV in vivo.
|
27417579 |
2016 |
Disorder of eye
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We hypothesized that inhibition of CYP2C activity will add to the protective effects of ω-3 LCPUFA on neovascular eye diseases.
|
27417579 |
2016 |
Hypertensive disease
|
0.040 |
Biomarker
|
group |
BEFREE |
The contribution of CYP2C gene subfamily involved in epoxygenase pathway of arachidonic acids metabolism to hypertension susceptibility in Russian population.
|
28513222 |
2017 |
Hypertensive disease
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Overall, nifedipine and verapamil blunts CSA hypertension but variably affected concomitantly enhanced EDHF-dependent renal vasodilations and alterations in CYP2C/CYP4A signaling.
|
28899749 |
2017 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues.
|
28954402 |
2017 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
Biomarker
|
disease |
BEFREE |
These alterations induced by Type II diabetes in the endogenous pathway (CYP450) of arachidonic acid metabolism may increase the risk for cardiovascular disease by disrupting the fine equilibrium between cardioprotective (CYP2J/CYP2C-generated) and cardiotoxic (CYP4A/CYP4F-generated) metabolites of arachidonic acid.
|
29023376 |
2017 |
Cardiovascular Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
These alterations induced by Type II diabetes in the endogenous pathway (CYP450) of arachidonic acid metabolism may increase the risk for cardiovascular disease by disrupting the fine equilibrium between cardioprotective (CYP2J/CYP2C-generated) and cardiotoxic (CYP4A/CYP4F-generated) metabolites of arachidonic acid.
|
29023376 |
2017 |
Coronary heart disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our preliminary results demonstrate that polymorphisms of genes encoding CYP2C subfamily represent potential genetic markers of CHD susceptibility.
|
28687336 |
2017 |
Essential Hypertension
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Thus, genes of CYP2C subfamily are important genetic determinants of susceptibility to essential hypertension in Russians.
|
28513222 |
2017 |
Xerocytosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Non-genetic factor, omeprazole co-medication, was strongly associated with PHT-induced DRESS/DHS in addition to variants in HLA-B and CYP2C genes.
|
28391407 |
2017 |
DEAFNESS-HYPOGONADISM SYNDROME
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Non-genetic factor, omeprazole co-medication, was strongly associated with PHT-induced DRESS/DHS in addition to variants in HLA-B and CYP2C genes.
|
28391407 |
2017 |
Drug Hypersensitivity Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Non-genetic factor, omeprazole co-medication, was strongly associated with PHT-induced DRESS/DHS in addition to variants in HLA-B and CYP2C genes.
|
28391407 |
2017 |
Metabolic Diseases
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Furthermore, ATR induced CYP-related enzymes metabolism disorders by activating the nuclear xenobiotic receptors response (NXRs including AHR, CAR, and PXR) and increased expression of several CYP isoforms (including CYP1B1 and CYP2C18) and thereby producing mitochondrial dysfunction.
|
29865786 |
2018 |
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
This study investigated the prognostic value of CYP2C subfamily gene expression levels with HCC prognosis.
|
29479826 |
2018 |
Cholestasis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The constitutive androstane receptor (CAR)/pregnane X receptor (PXR)-CYP2B/CYP2C axis is activated in DKO livers but not in other cholestasis models.
|
29718219 |
2018 |
Ulcerative Colitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This study indicated that the presence of UC decreases CYP2C expression levels in the liver, thereby delaying the metabolism of CYP2C substrates, including phenytoin, and increasing blood concentrations of these substrates.
|
29130833 |
2018 |
Toxic Epidermal Necrolysis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Further multicenter studies and large prospective observational studies are, however, still required to determine the influence of CYP2C*3 on blood levels of PHT and its metabolites, and their association with SJS/TEN.
|
29274302 |
2018 |
Schwartz-Jampel Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Further multicenter studies and large prospective observational studies are, however, still required to determine the influence of CYP2C*3 on blood levels of PHT and its metabolites, and their association with SJS/TEN.
|
29274302 |
2018 |